Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hamuryudan, V.
space
  arrow  Yazici, H.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Mucocutaneous Lesions in the Behcet Syndrome

right arrow Vedat Hamuryudan, MD; Cem Mat, MD; and Hasan Yazici, MD

15 November 1998 | Volume 129 Issue 10 | Page 836


TO THE EDITOR:

We agree with Demiroglu and colleagues that no single treatment exists for a cure or a long-lasting remission in the Behcet's syndrome and that more work toward this end is clearly needed. We also have no doubt that penicillin, if shown to be as effective as thalidomide, would definitely be less risky.

In 1989, an uncontrolled study suggested that penicillin might be effective in treating the Behcet syndrome (Okten S. Penicillin in the treatment of Behcet's disease. Presented at the Fifth International Conference on Behcet's Disease, 14-15 September 1989, Rochester, Minnesota). Later, a retrospective study at the Seventh Mediterranean Congress of Rheumatology [1] and two randomized studies published in peer-reviewed journals [2, 3] reported favorable results with penicillin in the Behcet syndrome, but none of these studies was blinded. We believe that a properly blinded study is necessary before penicillin can be considered optimal for this condition.

Finally, we are not sure, as Demiroglu and colleagues seem to be, about the long-lasting effects of interferon-{alpha}. In a pilot study that used each patient as his or her own control [4], we had shown a beneficial effect of systemic interferon-{alpha} therapy especially in controlling the arthritis of the Behcet syndrome. However, symptoms recurred after this therapy was stopped.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

University of Istanbul; Istanbul, Turkey


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Haznedaroglu IC, Demiroglu H, Ozcebe OI, Ozdemir O, Dundar SV. Benzathine penicillin in the prophylaxis and treatment of Behcet's disease [Abstract]. In: Boki KA, Drosos AA, Moutsopoulos HM, Tzioufas AG, Vlachoyiannopoulos PG, eds. Proceedings of the VIIth Mediterranean Congress of Rheumatology, 16-18 June 1994. Athens: Monduzzi Editore; 1994:185-8.

2. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology. 1996; 192:125-8.

3. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease: a randomized controlled trial. Arthritis Rheum. 1996; 39:2062-5.

4. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, et al. Systemic interferon {alpha} 2b treatment in Behcet's syndrome. J Rheumatol. 1994; 21:1098-100.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.




This article has been cited by other articles:


Home page
Ann Rheum DisHome page
N M Moutsopoulos, N Angelov, V Sankar, R A Leakan, S Pillemer, and S M Wahl
Immunological consequences of thalidomide treatment in Sjogren's syndrome
Ann Rheum Dis, January 1, 2006; 65(1): 112 - 114.
[Abstract] [Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hamuryudan, V.
space
  arrow  Yazici, H.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online